

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



華潤醫藥集團有限公司

China Resources Pharmaceutical Group Limited

(Incorporated in Hong Kong with limited liability)

(Stock Code: 3320)

CHANGE IN ARRANGEMENT IN RELATION TO THE RE-ELECTION OF DIRECTOR

Reference is made to the circular (the “**Circular**”), the notice of the annual general meeting (the “**AGM Notice**”) and the proxy form (the “**Proxy Form**”) all dated 18 April 2018 and the annual report (the “**Annual Report**”) dated 21 March 2018 for the year ended 31 December 2017 of China Resources Pharmaceutical Group Limited (the “**Company**”) in relation to, inter alia, the proposed re-election of Mr. WANG Chenyang (“**Mr. WANG**”) as a director of the Company (“**Director**”) to be considered at the annual general meeting of the Company scheduled to be held on 18 May 2018 (“**AGM**”). Unless otherwise defined, capitalized terms used in this announcement shall have the same meanings as those defined in the Circular.

It was disclosed in the Circular and the Annual Report that, as one of the retiring Directors at the AGM, Mr. WANG would offer himself for re-election as a Director at the AGM.

Subsequent to the dispatch of the AGM Notice and the Circular, the board of Directors (“**Board**”) has been informed by Mr. WANG that, due to other work allocation by the Beijing State-Owned Capital Operations and Management Centre, he would not offer himself for re-election as a Director upon rotational retirement at the AGM. In light of Mr. WANG’s decision not to offer himself for re-election, the Board will withdraw the ordinary resolution numbered 3(2) “To re-elect Mr. WANG Chenyang as Director” from voting at the AGM.

Save for the foregoing, all information and content (including but not limited to the date, time and venue for holding the AGM) as set out in the Circular, the AGM Notice and the Proxy Form remain unchanged. The Proxy Form shall remain valid except that no poll will be taken or counted for ordinary resolution numbered 3(2).

For and on behalf of
China Resources Pharmaceutical Group Limited
WANG Chuncheng
Executive Director

Hong Kong, 16 May 2018

As of the date of this announcement, the Board comprises Mr. FU Yuning as chairman and non-executive Director, Mr. WANG Chuncheng, Mr. SONG Qing and Mr. LI Guohui as executive Directors, Mr. CHEN Rong, Mr. YU Zhongliang, Mr. WANG Chenyang and Ms. WANG Jing as non-executive Directors, Mdm. SHING Mo Han Yvonne, Mr. KWOK Kin Fun, Mr. FU Tingmei and Mr. ZHANG Kejian as independent non-executive Directors.